Anavex's publication supports clinical biomarker for anavex®2-73 in fragile x syndrome

Publication demonstrates the feasibility to use blood biomarkers to monitor response to anavex®2-73 (blarcamesine) in clinical trials of fragile x syndrome (major cause of autism) publication demonstrates the feasibility to use blood biomarkers to monitor response to anavex®2-73 (blarcamesine) in clinical trials of fragile x syndrome (major cause of autism)
AVXL Ratings Summary
AVXL Quant Ranking